Johnson & Johnson (JNJ) operating KPIs
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$273.20−2.00 (-0.73%)
Close on Oct 30, 2026Market cap $658.38BP/E 31.7Yield 1.88%
Johnson & Johnson scope 3 Cat 8 — Upstream leased assets (MT CO2e)
2025 Health for Humanity Report
Latest, FY2025
19,698.00
Period ended Dec 28, 2025
Change on a year earlier
-12.3%
22,450.00 in FY2024
History
3 years
Since FY2023
Sources
1
J&J 2025 Health for Humanity Report
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Scope 3 Cat 8 — Upstream leased assets (MT CO2e) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 28, 2025 | 19,698.00 | -12.3% | J&J 2025 Health for Humanity Report ↗ |
| FY2024 | Dec 29, 2024 | 22,450.00 | +2.8% | J&J 2025 Health for Humanity Report ↗ |
| FY2023 | Dec 31, 2023 | 21,837.00 | – | J&J 2025 Health for Humanity Report ↗ |
Cite this data
StockData. (2026). Johnson & Johnson Scope 3 Cat 8 — Upstream leased assets (MT CO2e), annual FY2023–FY2025 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/esg_ghg_s3_leased_assets
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.